Summary
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.
According to APO Research, The global Gene Therapy On Cardiovascular Disease market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Gene Therapy On Cardiovascular Disease is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Gene Therapy On Cardiovascular Disease is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Gene Therapy On Cardiovascular Disease is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Gene Therapy On Cardiovascular Disease is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals, Amgen, Spark Therapeutics, Akcea Therapeutics and bluebird bio, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Gene Therapy On Cardiovascular Disease, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Gene Therapy On Cardiovascular Disease, also provides the revenue of main regions and countries. Of the upcoming market potential for Gene Therapy On Cardiovascular Disease, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Gene Therapy On Cardiovascular Disease revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Gene Therapy On Cardiovascular Disease market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Gene Therapy On Cardiovascular Disease revenue, projected growth trends, production technology, application and end-user industry.
Gene Therapy On Cardiovascular Disease segment by Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Gene Therapy On Cardiovascular Disease segment by Type
Viral Gene Therapy
Non-Viral Gene Therapy
Gene Therapy On Cardiovascular Disease segment by Application
Heart Disease
Vascular Disease
Gene Therapy On Cardiovascular Disease segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapy On Cardiovascular Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gene Therapy On Cardiovascular Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapy On Cardiovascular Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Gene Therapy On Cardiovascular Disease in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Gene Therapy On Cardiovascular Disease company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gene Therapy On Cardiovascular Disease revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
1 Market Overview
1.1 Product Definition
1.2 Gene Therapy On Cardiovascular Disease Market by Type
1.2.1 Global Gene Therapy On Cardiovascular Disease Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Viral Gene Therapy
1.2.3 Non-Viral Gene Therapy
1.3 Gene Therapy On Cardiovascular Disease Market by Application
1.3.1 Global Gene Therapy On Cardiovascular Disease Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Heart Disease
1.3.3 Vascular Disease
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Gene Therapy On Cardiovascular Disease Market Dynamics
2.1 Gene Therapy On Cardiovascular Disease Industry Trends
2.2 Gene Therapy On Cardiovascular Disease Industry Drivers
2.3 Gene Therapy On Cardiovascular Disease Industry Opportunities and Challenges
2.4 Gene Therapy On Cardiovascular Disease Industry Restraints
3 Global Growth Perspective
3.1 Global Gene Therapy On Cardiovascular Disease Market Perspective (2019-2030)
3.2 Global Gene Therapy On Cardiovascular Disease Growth Trends by Region
3.2.1 Global Gene Therapy On Cardiovascular Disease Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Gene Therapy On Cardiovascular Disease Market Size by Region (2019-2024)
3.2.3 Global Gene Therapy On Cardiovascular Disease Market Size by Region (2025-2030)
4 Competitive Landscape by Players
4.1 Global Gene Therapy On Cardiovascular Disease Revenue by Players
4.1.1 Global Gene Therapy On Cardiovascular Disease Revenue by Players (2019-2024)
4.1.2 Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Players (2019-2024)
4.1.3 Global Gene Therapy On Cardiovascular Disease Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Gene Therapy On Cardiovascular Disease Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Gene Therapy On Cardiovascular Disease Key Players Headquarters & Area Served
4.4 Global Gene Therapy On Cardiovascular Disease Players, Product Type & Application
4.5 Global Gene Therapy On Cardiovascular Disease Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Gene Therapy On Cardiovascular Disease Market CR5 and HHI
4.6.2 Global Top 5 and 10 Gene Therapy On Cardiovascular Disease Players Market Share by Revenue in 2023
4.6.3 2023 Gene Therapy On Cardiovascular Disease Tier 1, Tier 2, and Tier 3
5 Gene Therapy On Cardiovascular Disease Market Size by Type
5.1 Global Gene Therapy On Cardiovascular Disease Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Gene Therapy On Cardiovascular Disease Revenue by Type (2019-2030)
5.3 Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2019-2030)
6 Gene Therapy On Cardiovascular Disease Market Size by Application
6.1 Global Gene Therapy On Cardiovascular Disease Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Gene Therapy On Cardiovascular Disease Revenue by Application (2019-2030)
6.3 Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2019-2030)
7 Company Profiles
7.1 Biogen
7.1.1 Biogen Comapny Information
7.1.2 Biogen Business Overview
7.1.3 Biogen Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2019-2024)
7.1.4 Biogen Gene Therapy On Cardiovascular Disease Product Portfolio
7.1.5 Biogen Recent Developments
7.2 Novartis
7.2.1 Novartis Comapny Information
7.2.2 Novartis Business Overview
7.2.3 Novartis Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2019-2024)
7.2.4 Novartis Gene Therapy On Cardiovascular Disease Product Portfolio
7.2.5 Novartis Recent Developments
7.3 Gilead Sciences
7.3.1 Gilead Sciences Comapny Information
7.3.2 Gilead Sciences Business Overview
7.3.3 Gilead Sciences Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2019-2024)
7.3.4 Gilead Sciences Gene Therapy On Cardiovascular Disease Product Portfolio
7.3.5 Gilead Sciences Recent Developments
7.4 Sarepta Therapeutics
7.4.1 Sarepta Therapeutics Comapny Information
7.4.2 Sarepta Therapeutics Business Overview
7.4.3 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2019-2024)
7.4.4 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
7.4.5 Sarepta Therapeutics Recent Developments
7.5 Alnylam Pharmaceuticals
7.5.1 Alnylam Pharmaceuticals Comapny Information
7.5.2 Alnylam Pharmaceuticals Business Overview
7.5.3 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2019-2024)
7.5.4 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product Portfolio
7.5.5 Alnylam Pharmaceuticals Recent Developments
7.6 Amgen
7.6.1 Amgen Comapny Information
7.6.2 Amgen Business Overview
7.6.3 Amgen Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2019-2024)
7.6.4 Amgen Gene Therapy On Cardiovascular Disease Product Portfolio
7.6.5 Amgen Recent Developments
7.7 Spark Therapeutics
7.7.1 Spark Therapeutics Comapny Information
7.7.2 Spark Therapeutics Business Overview
7.7.3 Spark Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2019-2024)
7.7.4 Spark Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
7.7.5 Spark Therapeutics Recent Developments
7.8 Akcea Therapeutics
7.8.1 Akcea Therapeutics Comapny Information
7.8.2 Akcea Therapeutics Business Overview
7.8.3 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2019-2024)
7.8.4 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
7.8.5 Akcea Therapeutics Recent Developments
7.9 bluebird bio
7.9.1 bluebird bio Comapny Information
7.9.2 bluebird bio Business Overview
7.9.3 bluebird bio Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2019-2024)
7.9.4 bluebird bio Gene Therapy On Cardiovascular Disease Product Portfolio
7.9.5 bluebird bio Recent Developments
7.10 Sunway Biotech
7.10.1 Sunway Biotech Comapny Information
7.10.2 Sunway Biotech Business Overview
7.10.3 Sunway Biotech Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2019-2024)
7.10.4 Sunway Biotech Gene Therapy On Cardiovascular Disease Product Portfolio
7.10.5 Sunway Biotech Recent Developments
7.11 SIBIONO
7.11.1 SIBIONO Comapny Information
7.11.2 SIBIONO Business Overview
7.11.3 SIBIONO Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2019-2024)
7.11.4 SIBIONO Gene Therapy On Cardiovascular Disease Product Portfolio
7.11.5 SIBIONO Recent Developments
7.12 AnGes
7.12.1 AnGes Comapny Information
7.12.2 AnGes Business Overview
7.12.3 AnGes Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2019-2024)
7.12.4 AnGes Gene Therapy On Cardiovascular Disease Product Portfolio
7.12.5 AnGes Recent Developments
7.13 Orchard Therapeutics
7.13.1 Orchard Therapeutics Comapny Information
7.13.2 Orchard Therapeutics Business Overview
7.13.3 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2019-2024)
7.13.4 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
7.13.5 Orchard Therapeutics Recent Developments
7.14 Human Stem Cells Institute
7.14.1 Human Stem Cells Institute Comapny Information
7.14.2 Human Stem Cells Institute Business Overview
7.14.3 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2019-2024)
7.14.4 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product Portfolio
7.14.5 Human Stem Cells Institute Recent Developments
8 North America
8.1 North America Gene Therapy On Cardiovascular Disease Revenue (2019-2030)
8.2 North America Gene Therapy On Cardiovascular Disease Revenue by Type (2019-2030)
8.2.1 North America Gene Therapy On Cardiovascular Disease Revenue by Type (2019-2024)
8.2.2 North America Gene Therapy On Cardiovascular Disease Revenue by Type (2025-2030)
8.3 North America Gene Therapy On Cardiovascular Disease Revenue Share by Type (2019-2030)
8.4 North America Gene Therapy On Cardiovascular Disease Revenue by Application (2019-2030)
8.4.1 North America Gene Therapy On Cardiovascular Disease Revenue by Application (2019-2024)
8.4.2 North America Gene Therapy On Cardiovascular Disease Revenue by Application (2025-2030)
8.5 North America Gene Therapy On Cardiovascular Disease Revenue Share by Application (2019-2030)
8.6 North America Gene Therapy On Cardiovascular Disease Revenue by Country
8.6.1 North America Gene Therapy On Cardiovascular Disease Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Gene Therapy On Cardiovascular Disease Revenue by Country (2019-2024)
8.6.3 North America Gene Therapy On Cardiovascular Disease Revenue by Country (2025-2030)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Gene Therapy On Cardiovascular Disease Revenue (2019-2030)
9.2 Europe Gene Therapy On Cardiovascular Disease Revenue by Type (2019-2030)
9.2.1 Europe Gene Therapy On Cardiovascular Disease Revenue by Type (2019-2024)
9.2.2 Europe Gene Therapy On Cardiovascular Disease Revenue by Type (2025-2030)
9.3 Europe Gene Therapy On Cardiovascular Disease Revenue Share by Type (2019-2030)
9.4 Europe Gene Therapy On Cardiovascular Disease Revenue by Application (2019-2030)
9.4.1 Europe Gene Therapy On Cardiovascular Disease Revenue by Application (2019-2024)
9.4.2 Europe Gene Therapy On Cardiovascular Disease Revenue by Application (2025-2030)
9.5 Europe Gene Therapy On Cardiovascular Disease Revenue Share by Application (2019-2030)
9.6 Europe Gene Therapy On Cardiovascular Disease Revenue by Country
9.6.1 Europe Gene Therapy On Cardiovascular Disease Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Gene Therapy On Cardiovascular Disease Revenue by Country (2019-2024)
9.6.3 Europe Gene Therapy On Cardiovascular Disease Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 China
10.1 China Gene Therapy On Cardiovascular Disease Revenue (2019-2030)
10.2 China Gene Therapy On Cardiovascular Disease Revenue by Type (2019-2030)
10.2.1 China Gene Therapy On Cardiovascular Disease Revenue by Type (2019-2024)
10.2.2 China Gene Therapy On Cardiovascular Disease Revenue by Type (2025-2030)
10.3 China Gene Therapy On Cardiovascular Disease Revenue Share by Type (2019-2030)
10.4 China Gene Therapy On Cardiovascular Disease Revenue by Application (2019-2030)
10.4.1 China Gene Therapy On Cardiovascular Disease Revenue by Application (2019-2024)
10.4.2 China Gene Therapy On Cardiovascular Disease Revenue by Application (2025-2030)
10.5 China Gene Therapy On Cardiovascular Disease Revenue Share by Application (2019-2030)
11 Asia (Excluding China)
11.1 Asia Gene Therapy On Cardiovascular Disease Revenue (2019-2030)
11.2 Asia Gene Therapy On Cardiovascular Disease Revenue by Type (2019-2030)
11.2.1 Asia Gene Therapy On Cardiovascular Disease Revenue by Type (2019-2024)
11.2.2 Asia Gene Therapy On Cardiovascular Disease Revenue by Type (2025-2030)
11.3 Asia Gene Therapy On Cardiovascular Disease Revenue Share by Type (2019-2030)
11.4 Asia Gene Therapy On Cardiovascular Disease Revenue by Application (2019-2030)
11.4.1 Asia Gene Therapy On Cardiovascular Disease Revenue by Application (2019-2024)
11.4.2 Asia Gene Therapy On Cardiovascular Disease Revenue by Application (2025-2030)
11.5 Asia Gene Therapy On Cardiovascular Disease Revenue Share by Application (2019-2030)
11.6 Asia Gene Therapy On Cardiovascular Disease Revenue by Country
11.6.1 Asia Gene Therapy On Cardiovascular Disease Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Gene Therapy On Cardiovascular Disease Revenue by Country (2019-2024)
11.6.3 Asia Gene Therapy On Cardiovascular Disease Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 Middle East, Africa, Latin America
12.1 MEALA Gene Therapy On Cardiovascular Disease Revenue (2019-2030)
12.2 MEALA Gene Therapy On Cardiovascular Disease Revenue by Type (2019-2030)
12.2.1 MEALA Gene Therapy On Cardiovascular Disease Revenue by Type (2019-2024)
12.2.2 MEALA Gene Therapy On Cardiovascular Disease Revenue by Type (2025-2030)
12.3 MEALA Gene Therapy On Cardiovascular Disease Revenue Share by Type (2019-2030)
12.4 MEALA Gene Therapy On Cardiovascular Disease Revenue by Application (2019-2030)
12.4.1 MEALA Gene Therapy On Cardiovascular Disease Revenue by Application (2019-2024)
12.4.2 MEALA Gene Therapy On Cardiovascular Disease Revenue by Application (2025-2030)
12.5 MEALA Gene Therapy On Cardiovascular Disease Revenue Share by Application (2019-2030)
12.6 MEALA Gene Therapy On Cardiovascular Disease Revenue by Country
12.6.1 MEALA Gene Therapy On Cardiovascular Disease Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Gene Therapy On Cardiovascular Disease Revenue by Country (2019-2024)
12.6.3 MEALA Gene Therapy On Cardiovascular Disease Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
List of Tables
Table 1. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Viral Gene Therapy Major Manufacturers
Table 2. Non-Viral Gene Therapy Major Manufacturers
Table 3. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 4. Heart Disease Major Manufacturers
Table 5. Vascular Disease Major Manufacturers
Table 6. Gene Therapy On Cardiovascular Disease Industry Trends
Table 7. Gene Therapy On Cardiovascular Disease Industry Drivers
Table 8. Gene Therapy On Cardiovascular Disease Industry Opportunities and Challenges
Table 9. Gene Therapy On Cardiovascular Disease Industry Restraints
Table 10. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 11. Global Gene Therapy On Cardiovascular Disease Market Size by Region (2019-2024) & (US$ Million)
Table 12. Global Gene Therapy On Cardiovascular Disease Market Share by Region (2019-2024)
Table 13. Global Gene Therapy On Cardiovascular Disease Market Size by Region (2025-2030) & (US$ Million)
Table 14. Global Gene Therapy On Cardiovascular Disease Market Share by Region (2025-2030)
Table 15. Global Gene Therapy On Cardiovascular Disease Revenue by Players (US$ Million) & (2019-2024)
Table 16. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Players (2019-2024)
Table 17. Global Gene Therapy On Cardiovascular Disease Key Players Ranking, 2022 VS 2023 VS 2024
Table 18. Global Gene Therapy On Cardiovascular Disease Key Players Headquarters & Area Served
Table 19. Global Gene Therapy On Cardiovascular Disease Players, Product Type & Application
Table 20. Global Gene Therapy On Cardiovascular Disease Players Commercialization Time
Table 21. Global Players Market Concentration Ratio (CR5 and HHI)
Table 22. Global Gene Therapy On Cardiovascular Disease by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 23. Global Gene Therapy On Cardiovascular Disease Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Gene Therapy On Cardiovascular Disease Revenue by Type (2019-2024) & (US$ Million)
Table 25. Global Gene Therapy On Cardiovascular Disease Revenue by Type (2025-2030) & (US$ Million)
Table 26. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 27. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 28. Global Gene Therapy On Cardiovascular Disease Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Gene Therapy On Cardiovascular Disease Revenue by Application (2019-2024) & (US$ Million)
Table 30. Global Gene Therapy On Cardiovascular Disease Revenue by Application (2025-2030) & (US$ Million)
Table 31. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 32. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 33. Biogen Company Information
Table 34. Biogen Business Overview
Table 35. Biogen Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 36. Biogen Gene Therapy On Cardiovascular Disease Product Portfolio
Table 37. Biogen Recent Development
Table 38. Novartis Company Information
Table 39. Novartis Business Overview
Table 40. Novartis Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 41. Novartis Gene Therapy On Cardiovascular Disease Product Portfolio
Table 42. Novartis Recent Development
Table 43. Gilead Sciences Company Information
Table 44. Gilead Sciences Business Overview
Table 45. Gilead Sciences Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 46. Gilead Sciences Gene Therapy On Cardiovascular Disease Product Portfolio
Table 47. Gilead Sciences Recent Development
Table 48. Sarepta Therapeutics Company Information
Table 49. Sarepta Therapeutics Business Overview
Table 50. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 51. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
Table 52. Sarepta Therapeutics Recent Development
Table 53. Alnylam Pharmaceuticals Company Information
Table 54. Alnylam Pharmaceuticals Business Overview
Table 55. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 56. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product Portfolio
Table 57. Alnylam Pharmaceuticals Recent Development
Table 58. Amgen Company Information
Table 59. Amgen Business Overview
Table 60. Amgen Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 61. Amgen Gene Therapy On Cardiovascular Disease Product Portfolio
Table 62. Amgen Recent Development
Table 63. Spark Therapeutics Company Information
Table 64. Spark Therapeutics Business Overview
Table 65. Spark Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 66. Spark Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
Table 67. Spark Therapeutics Recent Development
Table 68. Akcea Therapeutics Company Information
Table 69. Akcea Therapeutics Business Overview
Table 70. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 71. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
Table 72. Akcea Therapeutics Recent Development
Table 73. bluebird bio Company Information
Table 74. bluebird bio Business Overview
Table 75. bluebird bio Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 76. bluebird bio Gene Therapy On Cardiovascular Disease Product Portfolio
Table 77. bluebird bio Recent Development
Table 78. Sunway Biotech Company Information
Table 79. Sunway Biotech Business Overview
Table 80. Sunway Biotech Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 81. Sunway Biotech Gene Therapy On Cardiovascular Disease Product Portfolio
Table 82. Sunway Biotech Recent Development
Table 83. SIBIONO Company Information
Table 84. SIBIONO Business Overview
Table 85. SIBIONO Gene Therapy On Cardiovascular Disease Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 86. SIBIONO Gene Therapy On Cardiovascular Disease Product Portfolio
Table 87. SIBIONO Recent Development
Table 88. AnGes Company Information
Table 89. AnGes Business Overview
Table 90. AnGes Gene Therapy On Cardiovascular Disease Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 91. AnGes Gene Therapy On Cardiovascular Disease Product Portfolio
Table 92. AnGes Recent Development
Table 93. Orchard Therapeutics Company Information
Table 94. Orchard Therapeutics Business Overview
Table 95. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 96. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
Table 97. Orchard Therapeutics Recent Development
Table 98. Human Stem Cells Institute Company Information
Table 99. Human Stem Cells Institute Business Overview
Table 100. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 101. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product Portfolio
Table 102. Human Stem Cells Institute Recent Development
Table 103. North America Gene Therapy On Cardiovascular Disease Revenue by Type (2019-2024) & (US$ Million)
Table 104. North America Gene Therapy On Cardiovascular Disease Revenue by Application (2019-2024) & (US$ Million)
Table 105. North America Gene Therapy On Cardiovascular Disease Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 106. North America Gene Therapy On Cardiovascular Disease Revenue by Country (2019-2024) & (US$ Million)
Table 107. North America Gene Therapy On Cardiovascular Disease Revenue by Country (2025-2030) & (US$ Million)
Table 108. Europe Gene Therapy On Cardiovascular Disease Revenue by Type (2019-2024) & (US$ Million)
Table 109. Europe Gene Therapy On Cardiovascular Disease Revenue by Application (2019-2024) & (US$ Million)
Table 110. Europe Gene Therapy On Cardiovascular Disease Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 111. Europe Gene Therapy On Cardiovascular Disease Revenue by Country (2019-2024) & (US$ Million)
Table 112. Europe Gene Therapy On Cardiovascular Disease Revenue by Country (2025-2030) & (US$ Million)
Table 113. China Gene Therapy On Cardiovascular Disease Revenue by Type (2019-2024) & (US$ Million)
Table 114. China Gene Therapy On Cardiovascular Disease Revenue by Application (2019-2024) & (US$ Million)
Table 115. Asia Gene Therapy On Cardiovascular Disease Revenue by Type (2019-2024) & (US$ Million)
Table 116. Asia Gene Therapy On Cardiovascular Disease Revenue by Application (2019-2024) & (US$ Million)
Table 117. Asia Gene Therapy On Cardiovascular Disease Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 118. Asia Gene Therapy On Cardiovascular Disease Revenue by Country (2019-2024) & (US$ Million)
Table 119. Asia Gene Therapy On Cardiovascular Disease Revenue by Country (2025-2030) & (US$ Million)
Table 120. MEALA Gene Therapy On Cardiovascular Disease Revenue by Type (2019-2024) & (US$ Million)
Table 121. MEALA Gene Therapy On Cardiovascular Disease Revenue by Application (2019-2024) & (US$ Million)
Table 122. MEALA Gene Therapy On Cardiovascular Disease Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 123. MEALA Gene Therapy On Cardiovascular Disease Revenue by Country (2019-2024) & (US$ Million)
Table 124. MEALA Gene Therapy On Cardiovascular Disease Revenue by Country (2025-2030) & (US$ Million)
Table 125. Research Programs/Design for This Report
Table 126. Authors List of This Report
Table 127. Secondary Sources
Table 128. Primary Sources
List of Figures
Figure 1. Gene Therapy On Cardiovascular Disease Product Picture
Figure 2. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Gene Therapy On Cardiovascular Disease Market Size Share 2019 VS 2023 VS 2030
Figure 4. Viral Gene Therapy Picture
Figure 5. Non-Viral Gene Therapy Picture
Figure 6. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 7. Global Gene Therapy On Cardiovascular Disease Market Size Share 2019 VS 2023 VS 2030
Figure 8. Heart Disease Picture
Figure 9. Vascular Disease Picture
Figure 10. Global Gene Therapy On Cardiovascular Disease Market Size (US$ Million) & (2019-2030)
Figure 11. Global Gene Therapy On Cardiovascular Disease Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Gene Therapy On Cardiovascular Disease Market Share by Region: 2019 VS 2023 VS 2030
Figure 13. Global Gene Therapy On Cardiovascular Disease Players Revenue Share Top 10 and Top 5 in 2023
Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 15. Global Gene Therapy On Cardiovascular Disease Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Gene Therapy On Cardiovascular Disease Revenue Market Share 2019 VS 2023 VS 2030
Figure 17. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2019-2030)
Figure 18. Global Gene Therapy On Cardiovascular Disease Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 20. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2019-2030)
Figure 21. North America Gene Therapy On Cardiovascular Disease Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America Gene Therapy On Cardiovascular Disease Revenue by Type (2025-2030) & (US$ Million)
Figure 23. North America Gene Therapy On Cardiovascular Disease Revenue Share by Type (2019-2030)
Figure 24. North America Gene Therapy On Cardiovascular Disease Revenue by Application (2025-2030) & (US$ Million)
Figure 25. North America Gene Therapy On Cardiovascular Disease Revenue Share by Application (2019-2030)
Figure 26. North America Gene Therapy On Cardiovascular Disease Revenue Share by Country (2019-2030)
Figure 27. United States Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 28. Canada Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 29. Europe Gene Therapy On Cardiovascular Disease Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 30. Europe Gene Therapy On Cardiovascular Disease Revenue by Type (2025-2030) & (US$ Million)
Figure 31. Europe Gene Therapy On Cardiovascular Disease Revenue Share by Type (2019-2030)
Figure 32. Europe Gene Therapy On Cardiovascular Disease Revenue by Application (2025-2030) & (US$ Million)
Figure 33. Europe Gene Therapy On Cardiovascular Disease Revenue Share by Application (2019-2030)
Figure 34. Europe Gene Therapy On Cardiovascular Disease Revenue Share by Country (2019-2030)
Figure 35. Germany Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 36. France Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 37. U.K. Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 38. Italy Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 39. Russia Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 40. Nordic Countries Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. China Gene Therapy On Cardiovascular Disease Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 42. China Gene Therapy On Cardiovascular Disease Revenue by Type (2025-2030) & (US$ Million)
Figure 43. China Gene Therapy On Cardiovascular Disease Revenue Share by Type (2019-2030)
Figure 44. China Gene Therapy On Cardiovascular Disease Revenue by Application (2025-2030) & (US$ Million)
Figure 45. China Gene Therapy On Cardiovascular Disease Revenue Share by Application (2019-2030)
Figure 46. Asia Gene Therapy On Cardiovascular Disease Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 47. Asia Gene Therapy On Cardiovascular Disease Revenue by Type (2025-2030) & (US$ Million)
Figure 48. Asia Gene Therapy On Cardiovascular Disease Revenue Share by Type (2019-2030)
Figure 49. Asia Gene Therapy On Cardiovascular Disease Revenue by Application (2025-2030) & (US$ Million)
Figure 50. Asia Gene Therapy On Cardiovascular Disease Revenue Share by Application (2019-2030)
Figure 51. Asia Gene Therapy On Cardiovascular Disease Revenue Share by Country (2019-2030)
Figure 52. Japan Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 53. South Korea Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 54. India Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 55. Australia Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 56. China Taiwan Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 57. Southeast Asia Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. MEALA Gene Therapy On Cardiovascular Disease Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 59. MEALA Gene Therapy On Cardiovascular Disease Revenue by Type (2025-2030) & (US$ Million)
Figure 60. MEALA Gene Therapy On Cardiovascular Disease Revenue Share by Type (2019-2030)
Figure 61. MEALA Gene Therapy On Cardiovascular Disease Revenue by Application (2025-2030) & (US$ Million)
Figure 62. MEALA Gene Therapy On Cardiovascular Disease Revenue Share by Application (2019-2030)
Figure 63. MEALA Gene Therapy On Cardiovascular Disease Revenue Share by Country (2019-2030)
Figure 64. Mexico Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 65. South Korea Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 66. Brazil Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 67. Israel Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 68. Argentina Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 69. Colombia Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 70. Turkey Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. Saudi Arabia Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. UAE Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. Years Considered
Figure 74. Research Process
Figure 75. Key Executives Interviewed
